• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/3/21 9:29:08 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ICCC alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

                

    IMMUCELL CORP /DE/


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    452525306


    (CUSIP Number)

    December 31, 2020


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 452525306

    1. NAMES OF REPORTING PERSONS

    Wellington Trust Company, NA
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%
    12. TYPE OF REPORTING PERSON

    BK

    Item 1.
    (a) Name of Issuer
    IMMUCELL CORP /DE/
    (b) Address of Issuer's Principal Executive Offices
    56 Evergreen Drive
    Portland, ME 04103
    Item 2.
    (a) Name of Person Filing
    Wellington Trust Company, NA
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    United States
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    452525306
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [X] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    0
    (b) Percent of Class:
    0.00%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of 0
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed by Wellington Trust Company, NA, in its capacity as investment adviser, are owned of record by clients of Wellington Trust Company, NA. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not Applicable.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Trust Company, NA
    By: /s/ Matthew N. Shea
    Name: Matthew N. Shea
    Title: Authorized Person
    Date: February 15, 2021

    Get the next $ICCC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICCC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICCC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

      PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securities and Exchange Commission ("SEC") on April 24, 2025. The Annual Meeting will be held by remote communication in the form of a telephone conference call and a li

      6/5/25 6:30:00 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 million compared to the first quarter of 2024.During the six-month period ended March 31, 2025, product sales increased by 28% to approximately $15.8 million compared to the six-month period en

      5/14/25 4:05:00 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (inter

      5/12/25 8:42:13 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Leadership Updates

    Live Leadership Updates

    See more
    • ImmuCell Hires Chief Financial Officer

      PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activ

      4/7/25 9:00:00 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Appoints Bryan K. Gathagan to Board of Directors

      PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix

      6/21/23 4:05:22 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    SEC Filings

    See more
    • SEC Form 10-Q filed by ImmuCell Corporation

      10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)

      5/14/25 4:06:03 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

      5/14/25 4:05:26 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by ImmuCell Corporation

      DEF 14A - IMMUCELL CORP /DE/ (0000811641) (Filer)

      4/24/25 4:08:14 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by ImmuCell Corporation

      SC 13D - IMMUCELL CORP /DE/ (0000811641) (Subject)

      8/27/24 4:32:59 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by ImmuCell Corporation (Amendment)

      SC 13D/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

      4/16/21 3:21:48 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

      2/4/21 11:27:59 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Fiori Timothy C

      4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

      4/23/25 12:53:40 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Fiori Timothy C

      3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

      4/7/25 4:15:45 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Wainman Paul R

      4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

      9/24/24 8:31:01 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ICCC
    Financials

    Live finance-specific insights

    See more
    • ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

      PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securities and Exchange Commission ("SEC") on April 24, 2025. The Annual Meeting will be held by remote communication in the form of a telephone conference call and a li

      6/5/25 6:30:00 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 million compared to the first quarter of 2024.During the six-month period ended March 31, 2025, product sales increased by 28% to approximately $15.8 million compared to the six-month period en

      5/14/25 4:05:00 PM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

      PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (inter

      5/12/25 8:42:13 AM ET
      $ICCC
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care